AU2017318669B2 - Methods and composition for the prediction of the activity of enzastaurin - Google Patents

Methods and composition for the prediction of the activity of enzastaurin Download PDF

Info

Publication number
AU2017318669B2
AU2017318669B2 AU2017318669A AU2017318669A AU2017318669B2 AU 2017318669 B2 AU2017318669 B2 AU 2017318669B2 AU 2017318669 A AU2017318669 A AU 2017318669A AU 2017318669 A AU2017318669 A AU 2017318669A AU 2017318669 B2 AU2017318669 B2 AU 2017318669B2
Authority
AU
Australia
Prior art keywords
treatment
snp
sequencing
subject
snps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017318669A
Other languages
English (en)
Other versions
AU2017318669A1 (en
Inventor
Wen Luo
Hong Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denovo Biopharma LLC
Original Assignee
Denovo Biopharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma LLC filed Critical Denovo Biopharma LLC
Publication of AU2017318669A1 publication Critical patent/AU2017318669A1/en
Application granted granted Critical
Publication of AU2017318669B2 publication Critical patent/AU2017318669B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017318669A 2016-09-01 2017-08-31 Methods and composition for the prediction of the activity of enzastaurin Ceased AU2017318669B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US62/382,734 2016-09-01
US201662414601P 2016-10-28 2016-10-28
US62/414,601 2016-10-28
PCT/US2017/049747 WO2018045240A1 (en) 2016-09-01 2017-08-31 Methods and composition for the prediction of the activity of enzastaurin

Publications (2)

Publication Number Publication Date
AU2017318669A1 AU2017318669A1 (en) 2019-03-07
AU2017318669B2 true AU2017318669B2 (en) 2023-04-20

Family

ID=59923555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017318669A Ceased AU2017318669B2 (en) 2016-09-01 2017-08-31 Methods and composition for the prediction of the activity of enzastaurin

Country Status (15)

Country Link
US (2) US11421280B2 (enExample)
EP (1) EP3507384B1 (enExample)
JP (3) JP7197915B2 (enExample)
KR (1) KR20190046935A (enExample)
CN (1) CN109952383B (enExample)
AU (1) AU2017318669B2 (enExample)
BR (1) BR112019003951A2 (enExample)
CA (1) CA3035386A1 (enExample)
JO (1) JOP20190025A1 (enExample)
MX (1) MX2019002377A (enExample)
PH (1) PH12019500422A1 (enExample)
RU (1) RU2019109011A (enExample)
SG (2) SG11201901762WA (enExample)
TW (2) TW202313973A (enExample)
WO (1) WO2018045240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
US20220193062A1 (en) * 2018-09-12 2022-06-23 Denovo Biopharma Llc Combination of enzastaurin and inhibitors of btk and uses thereof
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
TWI808838B (zh) * 2021-07-23 2023-07-11 高雄醫學大學 二代荷爾蒙藥物於治療攝護腺癌療效評估之臨床治療藥物預測暨推薦系統及方法
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
EP1309679A2 (en) * 2000-08-16 2003-05-14 Chiron Corporation Human genes and gene expression products
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
KR102006417B1 (ko) * 2011-01-31 2019-08-01 드노보 바이오마커스 인코포레이티드 게놈약학적 바이오마커 동정 방법
EP2718486A4 (en) * 2011-06-08 2014-12-31 Denovo Biopharma Hangzhou Ltd Co METHODS AND COMPOSITIONS FOR PREDICTING THE ACTIVITY OF A RETINOID RECEPTOR X MODULATOR
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ghesquieres. et al. Journal of Clinical Oncology; 2015; 33:33: 3930-3937. (Year: 2015). *

Also Published As

Publication number Publication date
PH12019500422A1 (en) 2019-05-27
RU2019109011A3 (enExample) 2021-01-22
AU2017318669A1 (en) 2019-03-07
MX2019002377A (es) 2019-09-05
CN109952383B (zh) 2024-01-05
CN109952383A (zh) 2019-06-28
JP7197915B2 (ja) 2022-12-28
BR112019003951A2 (pt) 2019-06-25
US11421280B2 (en) 2022-08-23
TW202313973A (zh) 2023-04-01
SG11201901762WA (en) 2019-03-28
US20230074781A1 (en) 2023-03-09
TWI771317B (zh) 2022-07-21
US20190233902A1 (en) 2019-08-01
TW201812125A (zh) 2018-04-01
JP2022173308A (ja) 2022-11-18
EP3507384B1 (en) 2023-08-30
JP2019528705A (ja) 2019-10-17
RU2019109011A (ru) 2020-10-05
SG10201912134TA (en) 2020-02-27
KR20190046935A (ko) 2019-05-07
CA3035386A1 (en) 2018-03-08
WO2018045240A1 (en) 2018-03-08
EP3507384A1 (en) 2019-07-10
JP2020188816A (ja) 2020-11-26
JOP20190025A1 (ar) 2019-02-19

Similar Documents

Publication Publication Date Title
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
CN102203296B (zh) 年龄相关的黄斑变性中的遗传多态性
US20230193388A1 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotranmitter transporters
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
HK1196399B (en) Method for discovering pharmacogenomic biomarkers
HK1196399A (en) Method for discovering pharmacogenomic biomarkers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired